Clinical trial
Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed…
NCT00459108 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00459108 |
|---|---|
| Title | Dasatinib in Treating Patients With Advanced Liver Cancer That Cannot Be Removed by Surgery |
| Official title | A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer |
| Intervention type | Drug |
| Interventions | dasatinib |
| Enrollment | 25 |
| Start date | Apr 1, 2007 |
| Primary completion | Apr 1, 2011 |
| Completion | Apr 1, 2011 |
| First posted | Apr 11, 2007 |
| Last update posted | Apr 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: